Novo Nordisk announced positive results from the PIONEER TEENS phase 3a trial, showing oral semaglutide significantly reduced blood sugar levels in children and adolescents aged 10-17 with type 2 diabetes. The trial demonstrated a 0.83% greater HbA1c reduction versus placebo at 26 weeks, with a safety profile consistent with adult trials. This marks the first oral GLP-1 receptor agonist therapy tested in this age group, addressing a critical treatment gap. Novo Nordisk plans to seek regulatory approval for label expansion of its Ozempic pill and Rybelsus in the US and EU later this year, potentially offering a new effective treatment option for young patients with type 2 diabetes.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
